Cytek Biosciences Falls Short of Q4 Financial Expectations
Cytek Biosciences reported financial results that missed analyst expectations on both earnings and revenue metrics. The company posted a GAAP earnings per share loss of $0.15, which fell short of analyst projections by $0.05.
Revenue for the reporting period came in at $44.1 million, missing analyst estimates by $0.2 million.
About Cytek Biosciences
Cytek Biosciences is a cell analysis solutions company that develops and manufactures flow cytometers and provides related services. The company's technology is used in research, clinical, and industrial applications for cell analysis and sorting.
The company went public in 2021 and trades on the NASDAQ stock exchange. Flow cytometry technology is used across various fields including immunology research, cancer research, and drug development.
The reported financial metrics represent the company's performance using Generally Accepted Accounting Principles (GAAP), which provides a standardized framework for financial reporting that allows for consistent comparison across companies and time periods.
